Importantly, off-the-shelf NK cell lines for specific malignancies are already available, such as CD38/BCMA-targeting FT576 line for multiple myeloma [267], and the CD19-targeting FT596 line for B cell malignancies [268]. The gene discussed is CD19; the disease is AL amyloidosis.